Silo Pharma partners with Fireblocks for secure management of its institutional cryptocurrency treasury platform.
Quiver AI Summary
Silo Pharma, Inc. has engaged Fireblocks as the custodian for its institutional crypto treasury platform, emphasizing the importance of enterprise-level security and governance. CEO Eric Weisblum noted that Fireblocks' institutional-grade infrastructure aligns with Silo's long-term strategy for managing digital assets, such as Bitcoin, Ethereum, and Solana, to enhance shareholder value. Fireblocks is recognized for securely facilitating over $6 trillion in digital asset transfers and provides a robust multi-layer security framework. The collaboration aims to leverage advanced technology for the effective management of Silo's crypto assets while the company continues its focus on developing treatments for underserved medical conditions.
Potential Positives
- Silo Pharma has engaged Fireblocks, a recognized leader in secure digital asset management, enhancing the security and governance of its institutional crypto treasury platform.
- The partnership with Fireblocks indicates a commitment to building long-term value for shareholders through a robust strategy for managing digital assets like Bitcoin, Ethereum, and Solana.
- Fireblocks' proven infrastructure and multi-layer security framework for custody solutions will likely instill greater confidence among investors and institutional partners.
Potential Negatives
- The engagement with Fireblocks indicates that Silo Pharma is transitioning to a digital asset treasury strategy, which may signal a shift away from its core biopharmaceutical focus, potentially confusing investors about the company's primary business model.
- The extensive reliance on forward-looking statements may raise concerns about the company's ability to meet its projections, highlighting uncertainty in its strategic direction and operational effectiveness.
- The statement does not provide any concrete details about the financial implications or expected outcomes of this partnership, which may leave investors questioning the tangible benefits for the company and its shareholders.
FAQ
What is Silo Pharma's engagement with Fireblocks?
Silo Pharma has engaged Fireblocks as a custodian for its institutional crypto treasury platform, ensuring enterprise-grade security.
What is the focus of Silo Pharma's therapeutic programs?
Silo Pharma focuses on addressing underserved conditions like stress-induced psychiatric disorders, chronic pain, and CNS diseases.
How does Fireblocks enhance Silo Pharma's crypto operations?
Fireblocks provides secure, institutional-grade infrastructure to support Silo's strategy for buying, staking, trading, and managing digital assets.
What digital assets is Silo Pharma managing with Fireblocks?
Silo Pharma is managing Bitcoin, Ethereum, and Solana as part of its treasury strategy with Fireblocks.
What achievements does Fireblocks have in the digital asset space?
Fireblocks has facilitated the secure transfer of over $6 trillion in digital assets, demonstrating its trusted infrastructure.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SILO Insider Trading Activity
$SILO insiders have traded $SILO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SILO stock by insiders over the last 6 months:
- ERIC WEISBLUM (Chief Executive Officer) purchased 10,000 shares for an estimated $4,329
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SILO Hedge Fund Activity
We have seen 8 institutional investors add shares of $SILO stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADVISORSHARES INVESTMENTS LLC added 60,000 shares (+48.3%) to their portfolio in Q2 2025, for an estimated $37,800
- TWO SIGMA SECURITIES, LLC added 43,219 shares (+inf%) to their portfolio in Q2 2025, for an estimated $27,227
- RENAISSANCE TECHNOLOGIES LLC removed 37,500 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $43,875
- URSA FUND MANAGEMENT, LLC added 37,500 shares (+inf%) to their portfolio in Q2 2025, for an estimated $23,625
- XTX TOPCO LTD added 26,823 shares (+inf%) to their portfolio in Q2 2025, for an estimated $16,898
- UBS GROUP AG removed 20,085 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $23,499
- CONNING INC. removed 20,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,600
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SARASOTA, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has engaged Fireblocks, an enterprise platform for building blockchain applications and managing digital asset operations, as custodian for its institutional crypto treasury platform.
“Our engagement with Fireblocks is expected to ensure that our newly deployed crypto treasury platform is built with enterprise grade security and governance standards,” said Silo CEO Eric Weisblum. “We believe that Fireblocks’ proven institutional-grade infrastructure makes them the right partner to support our long-term strategy for buying, staking, trading, and managing our digital assets as we seek to build long-term value for our shareholders.”
Fireblocks is a globally recognized platform in the digital assets space, having facilitated the secure transfer of more than $6 trillion to date. Its multi-layer security framework combines multi-party computation (MPC) technology, Intel SGX, a signature policy engine, and a deposit address authentication network—delivering one of the most trusted custody solutions available to institutional clients.
“Partnering with Silo reflects our commitment to delivering secure, institutional-grade infrastructure that enables long-term value creation in digital assets,” said Ezra Solomon, Senior Manager of Corporate Strategy at Fireblocks. “We’re pleased to support their Bitcoin, Ethereum, and Solana treasury strategy with the technology and safeguards needed to buy, stake, and manage assets at scale.”
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
silopharma.com
About Fireblocks
Fireblocks is an easy-to-use platform to create new blockchain-based products and manage day-to-day digital asset operations. Exchanges, banks, PSPs, lending desks, custodians, trading desks, and hedge funds can securely scale their digital asset operations through the Fireblocks Network and MPC-based Wallet Infrastructure. Fireblocks serves thousands of organizations in the financial, payments, and web3 space, has secured the transfer of over $6 trillion in digital assets and has a unique insurance policy that covers assets in storage and transit. Find out more at
www.fireblocks.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
[email protected]
